[go: up one dir, main page]

SG10201408401RA - Coiled coil and/or tether containing protein complexes and uses thereof - Google Patents

Coiled coil and/or tether containing protein complexes and uses thereof

Info

Publication number
SG10201408401RA
SG10201408401RA SG10201408401RA SG10201408401RA SG10201408401RA SG 10201408401R A SG10201408401R A SG 10201408401RA SG 10201408401R A SG10201408401R A SG 10201408401RA SG 10201408401R A SG10201408401R A SG 10201408401RA SG 10201408401R A SG10201408401R A SG 10201408401RA
Authority
SG
Singapore
Prior art keywords
coiled coil
protein complexes
containing protein
tether
complexes
Prior art date
Application number
SG10201408401RA
Inventor
Erin H Christensen
Dan L Eaton
Andrew C Vendel
Bernd Wranik
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG10201408401RA publication Critical patent/SG10201408401RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

COILED COIL AND/OR TETHER CONTAINING PROTEIN COMPLEXES AND USES THEREOF Abstract The invention provides engineered protein complexes constructed using a coiled coil and/or a tether and methods for making, using, and purifying such complexes, such as multispecific antibodies or other multispecific Fc containing complexes. [Fig. 5] 121
SG10201408401RA 2009-09-16 2010-09-16 Coiled coil and/or tether containing protein complexes and uses thereof SG10201408401RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24310509P 2009-09-16 2009-09-16
US26699209P 2009-12-04 2009-12-04

Publications (1)

Publication Number Publication Date
SG10201408401RA true SG10201408401RA (en) 2015-01-29

Family

ID=43759225

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201408401RA SG10201408401RA (en) 2009-09-16 2010-09-16 Coiled coil and/or tether containing protein complexes and uses thereof
SG2012018909A SG179196A1 (en) 2009-09-16 2010-09-16 Coiled coil and/or tether containing protein complexes and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012018909A SG179196A1 (en) 2009-09-16 2010-09-16 Coiled coil and/or tether containing protein complexes and uses thereof

Country Status (15)

Country Link
US (2) US20120302737A1 (en)
EP (1) EP2478013B1 (en)
JP (2) JP6091894B2 (en)
KR (1) KR20120108967A (en)
CN (2) CN102712696A (en)
AU (2) AU2010296018B2 (en)
BR (1) BR112012005893A2 (en)
CA (1) CA2781519A1 (en)
HK (1) HK1212362A1 (en)
IL (1) IL218574A0 (en)
MX (1) MX2012003396A (en)
NZ (2) NZ701769A (en)
RU (2) RU2573915C2 (en)
SG (2) SG10201408401RA (en)
WO (1) WO2011034605A2 (en)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
BRPI1014089A2 (en) 2009-04-02 2016-04-19 Roche Glycart Ag multispecific antibodies comprising full length antibodies and single chain fab fragments
DK2417156T3 (en) 2009-04-07 2015-03-02 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
DK2560683T4 (en) 2010-04-23 2022-08-29 Hoffmann La Roche PRODUCTION OF HETEROMULTIMERIC PROTEINS
CA2807278A1 (en) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JP5764677B2 (en) 2011-02-28 2015-08-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Antigen binding protein
CN103403025B (en) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 Monovalent antigen binding protein
ES2971444T3 (en) * 2011-10-11 2024-06-05 F Hoffmann Lar Roche Ag Improved assembly of bispecific antibodies
KR101963230B1 (en) * 2011-12-26 2019-03-29 삼성전자주식회사 Protein complex comprising multi-specific monoclonal antibodies
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
WO2013119966A2 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
RU2639287C2 (en) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Method for selection and obtaining of highly selective and multispecific targeting groups with specified properties, including at least two different binding groups, and their applications
KR20150030744A (en) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
CN104428416B (en) 2012-07-05 2019-01-29 弗·哈夫曼-拉罗切有限公司 expression and secretion system
EP2874652A4 (en) * 2012-07-23 2015-12-30 Zymeworks Inc IMMUNOGLOBULIN CONSTRUCTS COMPRISING SELECTIVE MATCHING OF LIGHT AND HEAVY CHAINS
AU2013293092A1 (en) * 2012-07-23 2015-02-26 Zymeworks Inc. Immunoglobulin constructs comprising selective pairing of the light and heavy chains
KR101963231B1 (en) * 2012-09-11 2019-03-28 삼성전자주식회사 Protein complex for preparing bispecific antibodies and method using thereof
DE102012024520B4 (en) 2012-09-28 2017-06-22 Lg Display Co., Ltd. An organic light-emitting display and method for removing image fouling therefrom
KR101911438B1 (en) * 2012-10-31 2018-10-24 삼성전자주식회사 Bispecific antigen binding protein complex and preparation methods of bispecific antibodies
CN110669136A (en) 2012-11-05 2020-01-10 全药工业株式会社 Method for producing antibody or antibody composition
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2014110368A1 (en) 2013-01-11 2014-07-17 The California Institute For Biomedical Research Bovine fusion antibodies
EP3003370B1 (en) 2013-05-28 2020-01-22 Dcb-Usa Llc Antibody locker for the inactivation of protein drug
US20160237156A1 (en) 2013-07-11 2016-08-18 The California Institute For Biomedical Research Immunoglobulin fusion proteins and compositions thereof
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
RU2016115866A (en) 2013-10-11 2017-11-16 Ф. Хоффманн-Ля Рош Аг MULTI-SPECIFIC ANTIBODIES WITH EXCHANGED DOMAINS AND SAME VARIABLE DOMAINS OF EASY CHAIN
EP3068430A4 (en) * 2013-11-13 2017-07-05 Zymeworks Inc. Methods using monovalent antigen binding constructs targeting her2
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody Molecules of PD-1 and Their Uses
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
JP2017507939A (en) 2014-02-21 2017-03-23 ジェネンテック， インコーポレイテッド Anti-IL-13 / IL-17 bispecific antibody and use thereof
CN103869080B (en) * 2014-03-06 2016-01-27 中国农业大学 chronic neurodegenerative disease early diagnosis marker and application
ME03558B (en) 2014-03-14 2020-07-20 Novartis Ag Antibody molecules to lag-3 and uses thereof
CN106661125B (en) 2014-05-02 2021-10-01 动量制药公司 Compositions and methods involving engineered Fc constructs
ES2955736T3 (en) 2014-05-06 2023-12-05 Hoffmann La Roche Production of heteromultimeric proteins using mammalian cells
HRP20192243T1 (en) 2014-07-03 2020-03-06 F. Hoffmann - La Roche Ag Polypeptide expression systems
WO2016044219A1 (en) * 2014-09-15 2016-03-24 Trustees Of Boston University Therapeutic and research application of pdcl3
PL3227332T3 (en) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Multispecific antibodies
KR101798747B1 (en) 2015-02-02 2017-11-17 성균관대학교산학협력단 Coiled coil protein and use thereof
BR112017021510A2 (en) 2015-04-06 2018-07-03 Acceleron Pharma Inc tgf-beta superfamily type I and type II receptor heteromultimers and their use
JP6810702B2 (en) 2015-04-06 2021-01-06 アクセルロン ファーマ インコーポレイテッド Single-arm type I and type II receptor fusion proteins and uses thereof
MA41919A (en) 2015-04-06 2018-02-13 Acceleron Pharma Inc ALK4 HETEROMULTIMERS: ACTRIIB AND THEIR USES
EP3302552A1 (en) 2015-06-02 2018-04-11 H. Hoffnabb-La Roche Ag Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
EP3371217B1 (en) 2015-11-08 2025-06-11 F. Hoffmann-La Roche AG Methods of screening for multispecific antibodies
TWI703160B (en) * 2015-11-30 2020-09-01 美商輝瑞股份有限公司 Antibodies and antibody fragments for site-specific conjugation
US12391759B2 (en) 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
EP3439741A4 (en) 2016-04-06 2020-05-06 Acceleron Pharma Inc. ALK7 ANTAGONISTS AND USES THEREOF
EP3445780A1 (en) 2016-04-20 2019-02-27 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
TWI827531B (en) 2016-04-20 2024-01-01 美商再生元醫藥公司 Compositions and methods for making antibodies based on use of expression-enhancing loci
KR102635635B1 (en) 2016-05-23 2024-02-14 모멘타 파머슈티컬스 인코포레이티드 Compositions and methods related to engineered fc constructs
AU2017296040C1 (en) 2016-07-15 2023-06-22 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
IL285146B (en) 2016-07-22 2022-09-01 Amgen Inc Methods of purifying fc-containing proteins
US11603394B2 (en) 2016-10-04 2023-03-14 University Of Florida Research Foundation, Incorporated Targeted effector proteins and uses thereof
JP2019529509A (en) 2016-10-05 2019-10-17 アクセレロン ファーマ インコーポレーテッド Compositions and methods for treating kidney disease
WO2018067874A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Variant actriib proteins and uses thereof
EP3522913A4 (en) 2016-10-05 2020-10-28 Acceleron Pharma Inc. ALK4: ACTRIIB HETEROMULTIMERS AND USES THEREOF
TW201829463A (en) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 anti-HLA-G antibody and use thereof
MX2019005772A (en) 2016-11-23 2019-10-02 Bioverativ Therapeutics Inc Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x.
CN110036034A (en) * 2016-12-09 2019-07-19 西雅图遗传学公司 Coiled-coil-masked bivalent antibodies
CN110650748B (en) 2017-01-06 2024-01-02 动量制药公司 Compositions and methods related to engineered Fc constructs
CN110325106A (en) * 2017-02-20 2019-10-11 加利福尼亚大学董事会 The determination of serology of asymptomatic cerebral ischemia
BR112019019813A2 (en) * 2017-03-30 2020-04-22 Univ Queensland chimeric molecules and uses thereof
BR112019018767A2 (en) 2017-04-03 2020-05-05 Hoffmann La Roche antibodies, bispecific antigen binding molecule, one or more isolated polynucleotides, one or more vectors, host cell, method for producing an antibody, pharmaceutical composition, uses, method for treating a disease in an individual and invention
LT3606954T (en) 2017-04-05 2022-09-26 F. Hoffmann-La Roche Ag Anti-lag3 antibodies
CN118994394A (en) 2017-06-12 2024-11-22 蓝鳍生物医药公司 Anti-IL 1RAP antibodies and antibody drug conjugates
EP3652209A2 (en) 2017-07-11 2020-05-20 Compass Therapeutics LLC Agonist antibodies that bind human cd137 and uses thereof
US12268736B2 (en) * 2017-09-07 2025-04-08 University Of Oslo Vaccine molecules
US11407797B2 (en) 2017-10-11 2022-08-09 University Of Florida Research Foundation, Incorporated Modified gal-1 proteins and uses thereof
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
AR113862A1 (en) 2017-12-01 2020-06-17 Seattle Genetics Inc ANTI-CD47 ANTIBODIES AND THEIR USES TO TREAT CANCER
CN111527107B (en) 2017-12-21 2024-10-01 豪夫迈·罗氏有限公司 Antibodies that bind HLA-A2/WT1
JP2021508471A (en) 2017-12-29 2021-03-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ How to Improve VEGF Receptor Blocking Selectivity of Anti-VEGF Antibodies
JP2021511782A (en) 2018-01-31 2021-05-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Stabilized immunoglobulin domain
EP3746480A1 (en) 2018-01-31 2020-12-09 F. Hoffmann-La Roche AG Bispecific antibodies comprising an antigen-binding site binding to lag3
TWI829667B (en) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 Antibodies binding to gprc5d
CN112236450B (en) * 2018-03-26 2025-07-22 广州呈源生物免疫技术有限公司 Compositions of target binding moieties and methods of use
MX2020010028A (en) 2018-03-29 2020-10-14 Genentech Inc Modulating lactogenic activity in mammalian cells.
AR115052A1 (en) 2018-04-18 2020-11-25 Hoffmann La Roche MULTI-SPECIFIC ANTIBODIES AND THE USE OF THEM
AR114789A1 (en) 2018-04-18 2020-10-14 Hoffmann La Roche ANTI-HLA-G ANTIBODIES AND THE USE OF THEM
CA3099450A1 (en) * 2018-05-08 2019-11-14 Amgen Inc. Bispecific antibodies with cleavable c-terminal charge-paired tags
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
AU2019272575A1 (en) 2018-05-21 2020-12-10 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by NK cells
KR20210025054A (en) * 2018-06-21 2021-03-08 샤턱 랩스 인코포레이티드 Heterodimeric proteins and uses thereof
MX2021005594A (en) 2018-11-13 2021-10-22 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof.
AU2019402097A1 (en) 2018-12-17 2021-06-10 Revitope Limited Twin immune cell engager
TWI881476B (en) 2018-12-21 2025-04-21 瑞士商赫孚孟拉羅股份公司 Antibodies binding to cd3
US20220073630A1 (en) 2018-12-28 2022-03-10 Hoffmann-La Roche, Inc. A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
EP3962924A1 (en) 2019-05-03 2022-03-09 Genentech, Inc. Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform
AR122263A1 (en) 2019-05-09 2022-08-31 Genentech Inc METHODS TO PRODUCE ANTIBODIES
US20220233709A1 (en) 2019-06-05 2022-07-28 Seagen Inc. Masked Antibody Formulations
US20220306727A1 (en) 2019-06-05 2022-09-29 Seagen Inc. Methods of Purifying Masked Antibodies
AR119382A1 (en) 2019-07-12 2021-12-15 Hoffmann La Roche PRE-TARGETING ANTIBODIES AND METHODS OF USE
AR119393A1 (en) 2019-07-15 2021-12-15 Hoffmann La Roche ANTIBODIES THAT BIND NKG2D
EP4004045A1 (en) 2019-07-31 2022-06-01 F. Hoffmann-La Roche AG Antibodies binding to gprc5d
PE20220394A1 (en) 2019-07-31 2022-03-18 Hoffmann La Roche ANTIBODIES THAT BIND TO GPRC5D
EP4019536A4 (en) 2019-08-19 2023-09-06 Nantong Yichen Biopharma. Co. Ltd. Immunocytokine, preparation for same, and uses thereof
CR20220156A (en) 2019-09-18 2022-05-23 Genentech Inc ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES AND METHODS OF USE
EP4057980A1 (en) 2019-11-15 2022-09-21 F. Hoffmann-La Roche AG Prevention of visible particle formation in aqueous protein solutions
PE20221282A1 (en) 2019-12-18 2022-09-05 Hoffmann La Roche ANTIBODIES THAT BIND HLA-A2/MAGE-A4
EP4076663A1 (en) 2019-12-18 2022-10-26 F. Hoffmann-La Roche AG Bispecific anti-ccl2 antibodies
CR20220334A (en) 2019-12-23 2022-08-26 Genentech Inc APOLIPOPROTEIN L1 SPECIFIC ANTIBODIES AND METHODS OF USE
AU2021208515A1 (en) 2020-01-15 2022-08-04 F. Hoffmann-La Roche Ag Methods to decrease impurities from recombinant protein manufacturing processes
CA3152165A1 (en) * 2020-02-24 2021-09-02 Christian-Benedikt GERHOLD Recombinant calprotectin
CN115315512A (en) 2020-03-26 2022-11-08 基因泰克公司 Modified mammalian cells with reduced host cell proteins
US20230265204A1 (en) 2020-04-24 2023-08-24 Hoffmann-La Roche Inc. Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
WO2021228917A1 (en) 2020-05-15 2021-11-18 F. Hoffmann-La Roche Ag Prevention of visible particle formation in parenteral protein solutions
EP4153130A1 (en) 2020-05-19 2023-03-29 F. Hoffmann-La Roche AG The use of chelators for the prevention of visible particle formation in parenteral protein solutions
AR122569A1 (en) 2020-06-08 2022-09-21 Hoffmann La Roche ANTI-HBV ANTIBODIES AND METHODS OF USE
WO2021255143A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and folr1
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
TWI852680B (en) 2020-06-19 2024-08-11 瑞士商赫孚孟拉羅股份公司 Antibodies binding to cd3 and cd19
AU2021291407A1 (en) 2020-06-19 2022-09-29 F. Hoffmann-La Roche Ag Antibodies binding to CD3
IL299161A (en) 2020-06-24 2023-02-01 Genentech Inc Apoptosis resistant cell lines
EP4178529A1 (en) 2020-07-07 2023-05-17 F. Hoffmann-La Roche AG Alternative surfactants as stabilizers for therapeutic protein formulations
PE20230434A1 (en) 2020-07-10 2023-03-08 Hoffmann La Roche ANTIBODIES THAT BIND TO CANCER CELLS AND DIRECT RADIONUCLEOTIDES TO THESE CELLS
WO2022016037A1 (en) 2020-07-17 2022-01-20 Genentech, Inc. Anti-notch2 antibodies and methods of use
KR20230056766A (en) 2020-08-28 2023-04-27 제넨테크, 인크. CRISPR/Cas9 multiple knockout of host cell proteins
KR20230109674A (en) 2020-11-16 2023-07-20 에프. 호프만-라 로슈 아게 FAB high mannose sugar form
PE20240819A1 (en) 2020-12-17 2024-04-18 Hoffmann La Roche ANTI-HLA-G ANTIBODIES AND THEIR USE
MX2023008084A (en) 2021-01-12 2023-07-13 Hoffmann La Roche Split antibodies which bind to cancer cells and target radionuclides to said cells.
WO2022152701A1 (en) 2021-01-13 2022-07-21 F. Hoffmann-La Roche Ag Combination therapy
WO2022169872A1 (en) 2021-02-03 2022-08-11 Genentech, Inc. Multispecific binding protein degrader platform and methods of use
WO2022187865A1 (en) * 2021-03-05 2022-09-09 Brigham Young University Method for controlling protein dimerization using an intramolecular to intermolecular conformational switch
AR125074A1 (en) 2021-03-12 2023-06-07 Genentech Inc ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, ANTI-KLK5/KLK7 MULTI-SPECIFIC ANTIBODIES AND METHODS OF USE
US20240190993A1 (en) 2021-04-14 2024-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve the anti-tumoral activity of macrophages
EP4322938A1 (en) 2021-04-14 2024-02-21 Institut National de la Santé et de la Recherche Médicale (INSERM) New method to improve nk cells cytotoxicity
IL307501A (en) 2021-04-19 2023-12-01 Hoffmann La Roche Modified mammalian cells
EP4341385A1 (en) 2021-05-21 2024-03-27 Genentech, Inc. Modified cells for the production of a recombinant product of interest
CA3221735A1 (en) 2021-06-18 2022-12-22 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
US20230197278A1 (en) 2021-07-13 2023-06-22 Genentech, Inc. Multi-variate model for predicting cytokine release syndrome
IL309856A (en) 2021-07-14 2024-02-01 Genentech Inc Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
CN117730102A (en) 2021-07-22 2024-03-19 豪夫迈·罗氏有限公司 Heterodimeric Fc domain antibodies
EP4379054A4 (en) 2021-07-27 2025-12-17 Stand Therapeutics Co Ltd PEPTIDE MARKER AND NUCLEIC ACID CODED FOR IT
CN117794953A (en) 2021-08-03 2024-03-29 豪夫迈·罗氏有限公司 Bispecific antibodies and methods of use
AR127887A1 (en) 2021-12-10 2024-03-06 Hoffmann La Roche ANTIBODIES THAT BIND CD3 AND PLAP
US20230322958A1 (en) 2022-01-19 2023-10-12 Genentech, Inc. Anti-Notch2 Antibodies and Conjugates and Methods of Use
WO2023205333A2 (en) * 2022-04-21 2023-10-26 Regents Of The University Of Minnesota Tumor necrosis factor receptor 1 antagonist polypeptides and methods of use thereof
AU2023312051A1 (en) 2022-07-22 2025-01-09 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof
AU2023356218A1 (en) 2022-10-07 2025-04-24 Genentech, Inc. Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
TW202423970A (en) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Combination therapy of a gprc5d tcb and cd38 antibodies
TW202423969A (en) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Combination therapy of a gprc5d tcb and proteasome inhibitors
TW202430211A (en) 2022-10-10 2024-08-01 瑞士商赫孚孟拉羅股份公司 Combination therapy of a gprc5d tcb and imids
WO2024120516A1 (en) 2022-12-08 2024-06-13 南京诺唯赞生物科技股份有限公司 Antibodies specifically binding to rsv
CN120693406A (en) 2022-12-12 2025-09-23 基因泰克公司 Optimizing peptide sialic acid content
US20240360229A1 (en) 2023-01-18 2024-10-31 Genentech, Inc. Multispecific antibodies and uses thereof
CN120569410A (en) 2023-01-25 2025-08-29 豪夫迈·罗氏有限公司 Antibodies that bind to CSF1R and CD3
CN120826234A (en) 2023-03-06 2025-10-21 豪夫迈·罗氏有限公司 Combination therapy of anti-EGFRvIII/anti-CD3 antibodies and tumor-targeted 4-1BB agonists
CN120858109A (en) 2023-03-10 2025-10-28 基因泰克公司 Fusions with proteases and uses thereof
WO2024192185A2 (en) * 2023-03-13 2024-09-19 The Trustees Of Columbia University In The City Of New York Compositions and methods for hiv latency reversal
WO2024206788A1 (en) 2023-03-31 2024-10-03 Genentech, Inc. Anti-alpha v beta 8 integrin antibodies and methods of use
CN118725121A (en) * 2023-03-31 2024-10-01 康码（上海）生物科技有限公司 A single-chain antibody and its in vitro synthesis system and application
AR132623A1 (en) 2023-05-08 2025-07-16 Hoffmann La Roche TARGETED INTERFERON FUSION PROTEINS AND METHODS OF USE
AR132687A1 (en) 2023-05-16 2025-07-23 Hoffmann La Roche PD-1-REGULATED IL-2 IMMUNOCONJUGATES AND THEIR USES
US20250011450A1 (en) 2023-06-22 2025-01-09 Genentech, Inc. Antibodies and uses thereof
CN116879425A (en) * 2023-06-26 2023-10-13 盛禾(中国)生物制药有限公司 Method for detecting purity of bispecific antibody protein
WO2025021838A1 (en) 2023-07-26 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025040567A1 (en) 2023-08-18 2025-02-27 F. Hoffmann-La Roche Ag Protease activatable fc domain binding molecules
AR133909A1 (en) 2023-09-25 2025-11-12 Hoffmann La Roche ANTIBODY THAT BINDS TO C3bBb
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
WO2025125386A1 (en) 2023-12-14 2025-06-19 F. Hoffmann-La Roche Ag Antibodies that bind to folr1 and methods of use
WO2025132503A1 (en) 2023-12-20 2025-06-26 F. Hoffmann-La Roche Ag Antibodies binding to ceacam5
WO2025137086A1 (en) 2023-12-20 2025-06-26 Genentech, Inc. Reducing alpha-gal
WO2025133042A2 (en) 2023-12-22 2025-06-26 F. Hoffmann-La Roche Ag Activatable fusion proteins and methods of use
WO2025181189A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025215060A1 (en) 2024-04-11 2025-10-16 F. Hoffmann-La Roche Ag Antibodies that specifically bind modified oligonucleotides
WO2025242657A1 (en) 2024-05-21 2025-11-27 Shape Biopharmaceuticals Ag Lipopeptide building blocks and aggregates
CN120040756A (en) * 2025-03-29 2025-05-27 常州嘉晖新材料科技有限公司 Preparation method of low-viscosity bio-based polyamide curing agent

Family Cites Families (369)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4150149A (en) 1976-11-29 1979-04-17 Professional Staff Association Of The Los Angeles County Harbor General Hospital Method and means for the early detection and diagnosis of certain types of cancers
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4868105A (en) 1985-12-11 1989-09-19 Chiron Corporation Solution phase nucleic acid sandwich assay
SE8505922D0 (en) 1985-12-13 1985-12-13 Kabigen Ab CONSTRUCTION OF AN IGG BINDING PROTEIN TO FACILITATE DOWNSTREAM PROCESSING USING PROTEIN ENGINEERING
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
IL86164A0 (en) 1987-04-28 1988-11-15 Tamir Biotechnology Ltd Improved dna probes
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
AU630076B2 (en) 1987-09-21 1992-10-22 Gen-Probe Incorporated Non-nucleotide linking reagents for nucleotide probes
US4914210A (en) 1987-10-02 1990-04-03 Cetus Corporation Oligonucleotide functionalizing reagents
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
ES2064374T3 (en) 1988-04-01 1995-02-01 Carter Wallace SPECIFIC SPLIT OF PEPTIDIC LINKS THROUGH ORGANIC PHOSPHINES THAT HAVE NUCLEOPHYLAL SIDE CHAINS.
FI891226A7 (en) 1988-04-28 1989-10-29 The Board Of Trustees Of The Leland Anti-T-cell receptor determinants for the treatment of autoimmune disease
FR2632955B1 (en) 1988-06-20 1991-12-27 Oris Ind NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS OF MARKED OLIGONUCLEOTIDES, OLIGONUCLEOTIDES OBTAINED FROM SUCH DERIVATIVES AND THEIR SYNTHESIS
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
FR2642074B1 (en) 1989-01-20 1994-04-29 Oris Ind POLYHYDROXYLATED MOLECULE DERIVATIVES FOR THE INTRODUCTION OF AT LEAST ONE BRANCH INTO AN OLIGONUCLEOTIDE
CA2046909A1 (en) 1989-03-21 1990-09-22 Mark D. Howell Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
AU652540B2 (en) 1989-07-19 1994-09-01 Xoma Corporation T cell receptor peptides as therapeutics for autoimmune and malignant disease
US5451463A (en) 1989-08-28 1995-09-19 Clontech Laboratories, Inc. Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
WO1991006305A1 (en) 1989-11-07 1991-05-16 Bristol-Myers Squibb Company Oligomeric immunoglobulins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992004053A1 (en) 1990-08-31 1992-03-19 Bristol-Myers Sqibb Company Homoconjugated immunoglobulins
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5290925A (en) 1990-12-20 1994-03-01 Abbott Laboratories Methods, kits, and reactive supports for 3' labeling of oligonucleotides
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE4118120A1 (en) 1991-06-03 1992-12-10 Behringwerke Ag TETRAVALENT BISPECIFIC RECEPTORS, THEIR PRODUCTION AND USE
US6511663B1 (en) 1991-06-11 2003-01-28 Celltech R&D Limited Tri- and tetra-valent monospecific antigen-binding proteins
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
CA2071137A1 (en) 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
IE922292A1 (en) 1991-07-15 1993-01-27 Jolla Pharma Modified phosphorous intermediates for providing functional¹groups on the 5' end of oligonucleotides
JP2562862B2 (en) 1991-08-28 1996-12-11 ベーリンガー・マンハイム・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Functional carriers for simultaneous synthesis and direct labeling of oligonucleotides as primers for template-dependent enzymatic nucleic acid synthesis
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
FI941572L (en) 1991-10-07 1994-05-27 Oncologix Inc Combination and method of use of anti-erbB-2 monoclonal antibodies
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ATE408012T1 (en) 1991-12-02 2008-09-15 Medical Res Council PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES
ATE419355T1 (en) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic MARKER FOR CANCER AND BIOSYNTHETIC BINDING PROTEIN FOR IT
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
WO1994004550A1 (en) 1992-08-21 1994-03-03 Triplex Pharmaceutical Corporation Cholesteryl-modified triple-helix forming oligonucleotides and uses thereof
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
JP3589665B2 (en) 1992-10-23 2004-11-17 イミュネックス・コーポレーション Preparation of soluble oligomeric proteins
EP1238986B1 (en) 1992-10-28 2008-06-25 Genentech, Inc. Use of Vascular endothelial cell growth factor antagonists
ES2091684T3 (en) 1992-11-13 1996-11-01 Idec Pharma Corp THERAPEUTIC APPLICATION OF CHEMICAL AND RADIO-MARKED ANTIBODIES AGAINST THE RESTRICTED DIFFERENTIATION ANTIGEN OF HUMAN B-LYMPHOCYTES FOR THE TREATMENT OF B-CELL LYMPHOMA.
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5532142A (en) * 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
DE4310141A1 (en) 1993-03-29 1994-10-06 Boehringer Mannheim Gmbh Homobidental trifunctional linkers
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
UA40577C2 (en) 1993-08-02 2001-08-15 Мерк Патент Гмбх Bispecific antigen molecule for lysis of tumor cells, method for preparing of bispecific antigen molecule, monoclonal antibody (variants), pharmaceutical preparation, pharmaceutical kit for lysis of tumor cells (variants), method of lysis of tumor cells
US5635602A (en) 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
CA2156924A1 (en) 1993-12-27 1995-07-06 Ton That Hai Water soluble non-immunogenic polyamide cross-linking agents
SE9400088D0 (en) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5824483A (en) * 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
WO1998006043A1 (en) 1996-08-02 1998-02-12 New York University A method and system for scripting interactive animated actors
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5849879A (en) 1994-11-03 1998-12-15 The Regents Of The University Of California Methods for the diagnosis of glaucoma
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
GB9504344D0 (en) 1995-03-03 1995-04-19 Unilever Plc Antibody fragment production
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
AU6163196A (en) 1995-06-07 1996-12-30 Smithkline Beecham Corporation Method for obtaining receptor agonist antibodies
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1997005156A1 (en) 1995-07-27 1997-02-13 Carsten Behrens A new achiral linker reagent for the incorporation of multiple amino groups into oligonucleotides
BR9606706A (en) 1995-10-16 1999-04-06 Unilever Nv Bispecific or bivalent antibody fragment analog use process to produce the same
AU7566396A (en) * 1995-11-16 1997-06-05 Boehringer Mannheim Gmbh Process for the preparation of peptides by way of streptavidin fusion proteins
US5736626A (en) 1996-01-29 1998-04-07 The Perkin-Elmer Corporation Solid support reagents for the direct synthesis of 3'-labeled polynucleotides
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
ES2225961T3 (en) 1996-04-04 2005-03-16 Unilever N.V. MULTIVALLY AND MULTI SPECIFIC ANTIGEN UNION PROTEIN.
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
EP0954606B1 (en) 1996-05-15 2003-10-15 Biogenex Laboratories Non-nucleotide linking reagents
ES2236634T3 (en) 1997-04-07 2005-07-16 Genentech, Inc. ANTI-VEGF ANTIBODIES.
EP2338915A3 (en) 1997-04-07 2011-10-12 Genentech, Inc. Anti-VEGF antibodies
EP0915987A2 (en) 1997-04-21 1999-05-19 Donlar Corporation POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1999006587A2 (en) 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999009055A2 (en) 1997-08-18 1999-02-25 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
WO1999037791A1 (en) 1998-01-23 1999-07-29 Vlaams Interuniversitair Instituut Voor Biotechnologie Multipurpose antibody derivatives
DE69937291T2 (en) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco ANTIBODY VARIANTS AND FRAGMENTS THEREOF
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (en) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト Engineering glycosylation of antibodies to improve antibody-dependent cytotoxicity
DE19819846B4 (en) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalent antibody constructs
US6117986A (en) 1998-06-10 2000-09-12 Intergen Company, L.P. Pyrimidines linked to a quencher
JP4113670B2 (en) 1998-06-22 2008-07-09 イムノメディクス， インコーポレイテッド Use of bispecific antibodies for pre-targeting diagnosis and pretargeting therapy
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
DK1783222T3 (en) 1998-10-23 2012-07-09 Kirin Amgen Inc Dimeric thrombopoietic peptidomimetics that bind to MPL receptor and have thrombopoietic activity
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
WO2000035956A1 (en) 1998-12-16 2000-06-22 Kyowa Hakko Kogyo Co., Ltd. Antihuman vegf monoclonal antibody
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
CN1232039A (en) 1999-04-02 1999-10-20 中国人民解放军海军总医院 Genetic engineering double specific antibody and its use
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
US6872806B1 (en) * 1999-06-25 2005-03-29 The Governors Of The University Of Alberta Polypeptide compositions formed using a coiled-coil template and methods of use
EP1074563A1 (en) 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
JP2003512821A (en) 1999-10-04 2003-04-08 メディカゴ インコーポレイテッド Methods for regulating transcription of exogenous genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6727356B1 (en) 1999-12-08 2004-04-27 Epoch Pharmaceuticals, Inc. Fluorescent quenching detection reagents and methods
CA2395660A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
EP1266014A2 (en) 2000-03-24 2002-12-18 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
DK1272647T3 (en) 2000-04-11 2014-12-15 Genentech Inc Multivalent antibodies and uses thereof
FR2807767B1 (en) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement MONOCLONAL ANTIBODIES ANTI-D
DE10021678A1 (en) 2000-05-05 2002-04-18 Stefan Duebel Recombinant polyspecific antibody constructs, useful for diagnosis and treatment of cancer, comprises three antibody fragments,where at least one comprises a disulfide bridge
WO2001090192A2 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
US6511809B2 (en) 2000-06-13 2003-01-28 E. I. Du Pont De Nemours And Company Method for the detection of an analyte by means of a nucleic acid reporter
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
DE10044373A1 (en) 2000-09-08 2002-03-21 Roche Diagnostics Gmbh New reagent for labeling nucleic acids
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
RU2430927C2 (en) 2000-10-20 2011-10-10 Тугаи Сейяку Кабусики Кайся Atomic compound capable of specifically identifying and cross linkinking cell surface molecule or intracellular molecule
US6610472B1 (en) * 2000-10-31 2003-08-26 Genetastix Corporation Assembly and screening of highly complex and fully human antibody repertoire in yeast
US8372954B2 (en) 2000-12-22 2013-02-12 National Research Council Of Canada Phage display libraries of human VH fragments
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
AU2002240751A1 (en) 2001-03-09 2002-09-24 William Herman Targeted ligands
US20020146415A1 (en) 2001-04-06 2002-10-10 Olson William C. Methods for inhibiting HIV-1 infection
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
ES2387546T3 (en) 2001-05-11 2012-09-25 Amgen Inc. Peptides and related molecules that bind to TALL-1
US6833441B2 (en) * 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US20030082547A1 (en) 2001-08-27 2003-05-01 Ewing Gregory J. Non-fluorescent quencher compounds and biomolecular assays
EP1293514B1 (en) 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
WO2003035833A2 (en) 2001-10-22 2003-05-01 Exelixis, Inc. Modifier of the p53 pathway and methods of use
JP2005289809A (en) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) Mutant heavy chain antibody
ATE430580T1 (en) 2001-10-25 2009-05-15 Genentech Inc GLYCOPROTEIN COMPOSITIONS
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003066660A2 (en) * 2002-02-05 2003-08-14 Immunolex Therapeutics Aps A PAIR OF ANTIBODY Fv FRAGMENTS STABILIZED BY COILED­COIL PEPTIDES
US20030157091A1 (en) * 2002-02-14 2003-08-21 Dyax Corporation Multi-functional proteins
US7139665B2 (en) 2002-02-27 2006-11-21 California Institute Of Technology Computational method for designing enzymes for incorporation of non natural amino acids into proteins
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
CA2484182A1 (en) 2002-04-29 2003-11-13 Genpat77 Pharmacogenetics Ag Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
KR100527334B1 (en) 2002-06-07 2005-11-09 (주)넥스젠 Novel Linker for Oligonucleotides
DE10227606B3 (en) 2002-06-20 2004-01-22 Bionethos Holding Gmbh Use of thrombopoietin for the cultivation of hepatocytes
DK1517921T3 (en) 2002-06-28 2006-10-09 Domantis Ltd Immunoglobulin single variable antigen binding domains and double specific constructs thereof
EP2286857A1 (en) 2002-07-02 2011-02-23 Panasonic Corporation Automatic administration instrument for medical use
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
HUE025086T2 (en) 2002-10-10 2016-02-29 Merck Patent Gmbh Pharmaceutical compositions directed to erb-b1 receptors
ES2260569T3 (en) 2002-12-20 2006-11-01 Roche Diagnostics Gmbh DERIVATIVES OF MANITOL AND GLUCITOL.
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
WO2004062602A2 (en) 2003-01-09 2004-07-29 Arizeke Pharmaceuticals Inc. Compositions and methods for targeted biological delivery of molecular carriers
PL224786B1 (en) 2003-01-22 2017-01-31 Glycart Biotechnology Ag Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
AU2004205684A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
BRPI0407446A (en) 2003-02-13 2006-01-31 Pharmacia Corp C-met Antibodies for cancer treatment
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
GB0305702D0 (en) 2003-03-12 2003-04-16 Univ Birmingham Bispecific antibodies
US7238792B2 (en) 2003-03-18 2007-07-03 Washington State University Research Foundation Foldable polymers as probes
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
RS20150135A1 (en) 2003-05-30 2015-08-31 Genentech Inc. TREATMENT WITH ANTI-VEGF ANTIBODIES
EP2395017A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
DK1639011T3 (en) 2003-06-30 2009-02-16 Domantis Ltd Pegylated Single-Domain Antibodies (dAb)
KR20060041205A (en) 2003-07-01 2006-05-11 이뮤노메딕스, 인코오포레이티드 Multivalent Carriers of Bispecific Antibodies
AR046071A1 (en) 2003-07-10 2005-11-23 Hoffmann La Roche ANTIBODIES AGAINST RECEIVER I OF THE INSULINAL TYPE GROWTH FACTOR AND THE USES OF THE SAME
US20050054048A1 (en) 2003-07-29 2005-03-10 Luigi Grasso Antibodies and methods for generating genetically altered antibodies with enhanced effector function
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
CA2534959A1 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
US20050064509A1 (en) 2003-09-23 2005-03-24 The Regents Of The University Of California Use of templated self assembly to create novel multifunctional species
CN1326881C (en) 2003-09-29 2007-07-18 中国人民解放军军事医学科学院基础医学研究所 Trivalent bispecific antibody and its preparation process and use
ES2831379T3 (en) 2003-10-09 2021-06-08 Ambrx Inc Polymeric derivatives for selective protein modification
ME01775B (en) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
NZ583292A (en) 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005051976A2 (en) 2003-11-20 2005-06-09 Ansata Therapeutics, Inc. Protein and peptide ligation processes and one-step purification processes
CA2494571C (en) 2003-12-02 2010-02-09 F.Hoffmann-La Roche Ag Oligonucleotides containing molecular rods
WO2005063816A2 (en) 2003-12-19 2005-07-14 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
BRPI0507159A (en) 2004-02-02 2007-06-26 Ambrx Inc modified human four-helix beam polypeptides and their uses
US7705150B2 (en) 2004-02-04 2010-04-27 Biosearch Technologies, Inc. Cyanine dyes
WO2005075514A2 (en) * 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
JP2008512352A (en) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド Novel tetravalent bispecific antibody
WO2006031370A2 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
BRPI0515589A (en) 2004-09-02 2008-07-29 Genentech Inc isolated antigen-binding polypeptides or antibodies, isolated antibody, method for negatively regulating fc (gamma) riib activity, treatment methods, isolated bispecific antibodies, methods of inhibiting an immune response, suppressing histamine release, fc (gamma) ri activation, fc (epsilon) ri receptor expression inhibition, composition and kit
ES2579805T3 (en) 2004-09-23 2016-08-16 Genentech, Inc. Antibodies and conjugates engineered with cysteine
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
JP5188808B2 (en) 2004-11-03 2013-04-24 アイリス モレキュラー ダイアグノスティクス， インコーポレイテッド Homogeneous analyte detection
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
HRP20110859T1 (en) 2004-12-21 2011-12-31 Medimmune Limited Antibodies directed to angiopoietin-2 and uses thereof
EP2402374A1 (en) 2005-02-07 2012-01-04 GlycArt Biotechnology AG Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
WO2006091209A2 (en) 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
EP1858914B1 (en) * 2005-02-24 2013-12-04 The University Of Queensland Peptide networks
CA2599265A1 (en) 2005-02-28 2006-09-08 Centocor, Inc. Heterodimeric protein binding compositions
JP5620626B2 (en) 2005-03-31 2014-11-05 中外製薬株式会社 Polypeptide production method by association control
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
AU2006236439B2 (en) 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
EP1877441A2 (en) 2005-04-26 2008-01-16 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
JP5255435B2 (en) 2005-04-26 2013-08-07 メディミューン，エルエルシー Regulation of antibody effector function by hinge domain manipulation
US7795009B2 (en) 2005-06-15 2010-09-14 Saint Louis University Three-component biosensors for detecting macromolecules and other analytes
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
TWI323734B (en) 2005-08-19 2010-04-21 Abbott Lab Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007031875A2 (en) 2005-08-26 2007-03-22 Glycart Biotechnology Ag Modified antigen binding molecules with altered cell signaling activity
JP5290756B2 (en) 2005-09-26 2013-09-18 メダレックス インコーポレイテッド Antibody-drug conjugates and uses thereof
WO2007044887A2 (en) 2005-10-11 2007-04-19 Transtarget, Inc. Method for producing a population of homogenous tetravalent bispecific antibodies
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
AR056142A1 (en) 2005-10-21 2007-09-19 Amgen Inc METHODS TO GENERATE THE MONOVALENT IGG ANTIBODY
ES2332139T3 (en) 2005-11-23 2010-01-27 F. Hoffmann-La Roche Ag POLINUCLEOTIDOS WITH PHOSPHATE MIMETIC.
JP5179373B2 (en) 2005-12-15 2013-04-10 アストラゼネカ アクチボラグ Combination of an angiopoietin-2 antagonist and a VEGF-A, KDR, and / or Flt1 antagonist for treating cancer
FR2894959B1 (en) 2005-12-15 2008-02-29 Galderma Res & Dev RAR-GAMMA RECEPTOR SELECTIVE AGONIST BIPHENYL DERIVATIVES
US9090648B2 (en) 2005-12-15 2015-07-28 Centre National De La Recherche Scientifique (Cnrs) Cationic oligonucleotides, automated methods for preparing same and their uses
US20070196274A1 (en) 2006-01-20 2007-08-23 Le Sun Immunoconjugates with improved efficacy for the treatment of diseases
GB0601513D0 (en) 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding molecules 3
AR059066A1 (en) 2006-01-27 2008-03-12 Amgen Inc COMBINATIONS OF THE ANGIOPOYETINE INHIBITOR -2 (ANG2) AND THE VASCULAR ENDOTELIAL GROWTH FACTOR INHIBITOR (VEGF)
JP2009526857A (en) 2006-02-15 2009-07-23 イムクローン・リミテッド・ライアビリティ・カンパニー Functional antibody
US7951918B2 (en) 2006-03-17 2011-05-31 Biogen Idec Ma Inc. Stabilized polypeptide compositions
EP1996236A2 (en) 2006-03-22 2008-12-03 National Institute of Immunology Novel bioconjugates as therapeutic agent and synthesis thereof
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
AU2007241729A1 (en) 2006-04-21 2007-11-01 Peoplebio, Inc. Method for differentially detecting multimeric form from monomeric form of multimer-forming polypeptides through three-dimensional interactions
US20070274985A1 (en) * 2006-05-26 2007-11-29 Stefan Dubel Antibody
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
WO2008005828A2 (en) 2006-06-30 2008-01-10 Novo Nordisk A/S PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS COMPRISING ANTIBODY MOLECULES SPECIFIC TO LAMININ-5 α3 CHAIN DOMAINS G1G2 AND USE THEREOF
AR062223A1 (en) 2006-08-09 2008-10-22 Glycart Biotechnology Ag MOLECULES OF ADHESION TO THE ANTIGEN THAT ADHER TO EGFR, VECTORS THAT CODE THEM, AND THEIR USES OF THESE
EP2407558A1 (en) 2006-10-31 2012-01-18 Noxxon Pharma AG Methods for the detection of a single- or double-stranded nucleic acid molecule
CN101205255A (en) 2006-12-14 2008-06-25 上海中信国健药业有限公司 Anti CD20 tetravalent antibody, preparation method and uses thereof
ES2582656T3 (en) 2006-12-19 2016-09-14 Genentech, Inc. VEGF specific antagonists for adjuvant and neoadjuvant therapy, and the treatment of early-stage tumors
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN101037671B (en) * 2007-02-14 2010-07-07 中国人民解放军军事医学科学院野战输血研究所 Hybridoma cell line and anti-human erythrocyte surface H antigen monoclonal antibodies generated thereof
HRP20131113T1 (en) 2007-02-16 2014-01-17 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
US10259860B2 (en) 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
WO2008137120A1 (en) 2007-05-03 2008-11-13 Tethys Bioscience, Inc. Binding reagents that contain small epitope binding molecules
BRPI0811857A2 (en) 2007-05-14 2014-10-21 Biogen Idec Inc SIMPLE CHAIN FC (SCFC) REGIONS, AGLUTINATION POLYPEPTIDES UNDERSTANDING THEM AND RELATED METHODS.
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
EP2626371A1 (en) 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
WO2009021754A2 (en) 2007-08-15 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Monospecific and multispecific antibodies and method of use
JP5702603B2 (en) 2007-08-15 2015-04-15 アイエスピー インヴェストメンツ インコーポレイテッドＩｓｐ Ｉｎｖｅｓｔｍｅｎｔｓ Ｉｎｃ． Polyvinylamide polymers containing polymerizable functional groups
DE102007038753A1 (en) 2007-08-16 2009-02-19 Giesecke & Devrient Gmbh Device and method for the calibration of a sensor system
CN101842116A (en) 2007-08-28 2010-09-22 比奥根艾迪克Ma公司 Compositions binding multiple epitopes of IGF-1R
ATE538129T1 (en) * 2007-09-07 2012-01-15 Complix N V NON-NATURAL PROTEINOUS STRUCTURE COMPRISING THREE NON-COVALENTLY ASSOCIATE PEPTIDES
EP2195461B1 (en) 2007-09-17 2015-05-27 Mattias Strömberg Magnetic detection of small entities
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US20090117105A1 (en) * 2007-11-01 2009-05-07 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Humanized anti-venezuelan equine encephalitis virus recombinant antibody
JP2011503000A (en) 2007-11-02 2011-01-27 セントコア・オーソ・バイオテツク・インコーポレーテツド Semi-synthetic GLP-1 peptide-Fc fusion construct, method and use thereof
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
PT2235064E (en) 2008-01-07 2016-03-01 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP2009181819A (en) 2008-01-31 2009-08-13 Hitachi High-Technologies Corp Charged particle beam equipment
EP2250278B1 (en) 2008-02-21 2023-04-05 Burnham Institute for Medical Research Methods and compositions related to peptides and proteins with c-terminal elements
JP4438875B2 (en) 2008-02-27 2010-03-24 三菱自動車工業株式会社 Vehicle fuel storage amount estimation device
AU2009234277B2 (en) 2008-04-11 2014-12-04 Aptevo Research And Development Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
CN102164960A (en) 2008-09-26 2011-08-24 罗氏格黎卡特股份公司 Bispecific anti-EGFR/anti-IGF-1R antibodies
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CA2739429C (en) 2008-10-14 2020-12-22 Lisa A. Damico Immunoglobulin variants and uses thereof
SG171812A1 (en) 2008-12-04 2011-07-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
US8940501B2 (en) 2009-01-30 2015-01-27 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
WO2010112194A1 (en) 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
BRPI1014089A2 (en) 2009-04-02 2016-04-19 Roche Glycart Ag multispecific antibodies comprising full length antibodies and single chain fab fragments
AU2010233994A1 (en) 2009-04-07 2011-09-22 Roche Glycart Ag Bispecific anti-ErbB-3/anti-c-Met antibodies
MX2011010158A (en) 2009-04-07 2011-10-17 Roche Glycart Ag Bispecific anti-erbb-2/anti-c-met antibodies.
DK2417156T3 (en) 2009-04-07 2015-03-02 Roche Glycart Ag Trivalent, bispecific antibodies
WO2010118169A2 (en) 2009-04-08 2010-10-14 The Regents Of The University Of California Human protein scaffold with controlled serum pharmacokinetics
CN102459346B (en) 2009-04-27 2016-10-26 昂考梅德药品有限公司 The method manufacturing heteromultimers molecule
RU2570633C2 (en) 2009-05-27 2015-12-10 Ф.Хоффманн-Ля Рош Аг Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
WO2011003780A1 (en) 2009-07-06 2011-01-13 F. Hoffmann-La Roche Ag Bi-specific digoxigenin binding antibodies
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
KR101508043B1 (en) 2009-09-29 2015-04-06 로슈 글리카트 아게 Bispecific death receptor agonistic antibodies
EP2519544A1 (en) 2009-12-29 2012-11-07 Emergent Product Development Seattle, LLC Polypeptide heterodimers and uses thereof
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
WO2012006635A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Processable single chain molecules and polypeptides made using same
RU2013110876A (en) 2010-08-24 2014-09-27 Рош Гликарт Аг ACTIVATED SPECIFIC ANTIBODIES
CA2807278A1 (en) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
RU2604490C2 (en) 2010-11-05 2016-12-10 Займворкс Инк. DESIGN OF STABLE HETERODIMERIC ANTIBODY WITH MUTATIONS IN Fc DOMAIN
ES2656969T3 (en) 2010-12-23 2018-03-01 F. Hoffmann-La Roche Ag Detection of a polypeptide dimer by a bivalent binding agent
JP6162044B2 (en) 2010-12-23 2017-07-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Binder
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN103403025B (en) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 Monovalent antigen binding protein
JP5764677B2 (en) 2011-02-28 2015-08-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Antigen binding protein
CA2840409A1 (en) 2011-06-28 2013-01-03 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
US20140155581A1 (en) 2011-07-06 2014-06-05 Medimmune, Llc Methods For Making Multimeric Polypeptides
JP5925893B2 (en) 2011-08-23 2016-05-25 ロシュ グリクアート アーゲー Bispecific antigen binding molecule
PT2748201T (en) 2011-08-23 2018-02-08 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
KR101886983B1 (en) 2011-08-23 2018-08-08 로슈 글리카트 아게 Fc-free antibodies comprising two fab fragments and methods of use
PL2794905T3 (en) 2011-12-20 2020-11-02 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
KR20140104963A (en) 2011-12-21 2014-08-29 에프. 호프만-라 로슈 아게 Rapid method for cloning and expression of cognate antibody variable region gene segments
WO2013119966A2 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
ES2743399T3 (en) 2012-04-20 2020-02-19 Merus Nv Methods and means for the production of Ig-like heterodimeric molecules
JP2015520168A (en) 2012-05-24 2015-07-16 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Multispecific antibody
RU2644263C2 (en) 2012-06-27 2018-02-08 Ф. Хоффманн-Ля Рош Аг Method for selection and production of selective and multispecific therapeutic molecules with specified properties, including, at least two, different target groups, and their applications
RU2639287C2 (en) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Method for selection and obtaining of highly selective and multispecific targeting groups with specified properties, including at least two different binding groups, and their applications
KR20150030744A (en) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
CA2878843A1 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Bispecific asymmetric heterodimers comprising anti-cd3 constructs
WO2014041072A1 (en) 2012-09-14 2014-03-20 F. Hoffmann-La Roche Ag Method for the production and selection of molecules comprising at least two different entities and uses thereof
EP2900696A1 (en) 2012-09-25 2015-08-05 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
KR20150130349A (en) 2013-03-15 2015-11-23 메르크 파텐트 게엠베하 Tetravalent bispecific antibodies
PL3227332T3 (en) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Multispecific antibodies

Also Published As

Publication number Publication date
RU2012114694A (en) 2013-10-27
CN102712696A (en) 2012-10-03
MX2012003396A (en) 2012-04-10
CN104945509A (en) 2015-09-30
AU2016210647A1 (en) 2016-08-18
US9994646B2 (en) 2018-06-12
RU2573915C2 (en) 2016-01-27
HK1212362A1 (en) 2016-06-10
JP6091894B2 (en) 2017-03-15
EP2478013B1 (en) 2018-10-24
AU2010296018B2 (en) 2016-05-05
RU2015153109A (en) 2019-01-15
WO2011034605A3 (en) 2011-08-04
JP2013505238A (en) 2013-02-14
AU2010296018A1 (en) 2012-04-12
KR20120108967A (en) 2012-10-05
SG179196A1 (en) 2012-04-27
NZ598962A (en) 2014-12-24
CA2781519A1 (en) 2011-03-24
EP2478013A2 (en) 2012-07-25
JP2016040260A (en) 2016-03-24
BR112012005893A2 (en) 2016-11-22
NZ701769A (en) 2016-06-24
US20120302737A1 (en) 2012-11-29
US20160002356A1 (en) 2016-01-07
EP2478013A4 (en) 2013-09-04
IL218574A0 (en) 2012-05-31
WO2011034605A2 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
SG10201408401RA (en) Coiled coil and/or tether containing protein complexes and uses thereof
TN2010000213A1 (en) Wise binding antibodies and epitopes
WO2009112245A9 (en) Antibody against the csf-1 r
MX2009012843A (en) Rsv-specific binding molecules and means for producing them.
MY161909A (en) Anti-her3 antibodies and uses thereof
TW200626171A (en) Fixed dosing of HER antibodies
MX2009004167A (en) Antibodies that bind cxcr7 epitopes.
WO2009140039A3 (en) Synthetic antibodies
WO2011075636A3 (en) Wise binding agents and epitopes
MY171841A (en) Antibody formulation
TW200745261A (en) Aqueous dispersions based on nitrocellulose-polyurethane particles
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
UA104459C2 (en) Anti-fgfr3 antibodies and methods using same
MY177564A (en) Anti-nr10 antibody and use thereof
TW200732349A (en) Anti-OX40L antibodies and methods using same
WO2008048970A3 (en) Synthetic antibodies
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
AU2012222463A8 (en) Cea antibodies
SG162728A1 (en) Tweak binding antibodies
MX2013009362A (en) Antibody against the csf-1r.
MX2009006252A (en) Tannate salt of rasagiline.
MX2012002458A (en) Humanized anti-cdcp1 antibodies.
WO2010006173A3 (en) Mineral amino acid polysaccharide complex
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use